The continuum between GH deficiency and GH insensitivity in children

Savage, Martin O.; Storr, Helen L; Backeljauw, Philippe

doi:10.1007/s11154-020-09590-5

Cited by 4 publications

(4 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, in patients receiving a true mean daily rhGH dose>0.03 mg/kg, the number of injections per week did not influence the height gain in the 12-month model, provided that the daily rhGH dose remained high enough; the mean daily dose in this category was 0.039 mg/kg.d. Patients with fair adherence (>5 injections/week) received a dose close to that prescribed, and this dose range is usually given to patients with some degree of resistance to treatment with rhGH ( 25 ). This resistance may be linked to the cause of short stature, and so this phenomenon might be “indication-dependent”.…”

Section: Discussionmentioning

confidence: 99%

“…The category with a dose<0.03 mg/kg.d was rhGH-sensitive and thus showed an adequate growth response to low-dose treatment. Accordingly, the growth response to treatment is usually good in rhGH-sensitive patients, such as those with profound GHD ( 25 ). In contrast, the category with a dose>0.03 mg/kg.d was probably rhGH-resistant: despite the administration of higher rhGH doses, the growth response to treatment may be smaller ( 25 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Yearly Height Gain Is Dependent on the Truly Received Dose of Growth Hormone and the Duration of Periods of Poor Adherence: Practical Lessons From the French Easypod™ Connect Multicenter Observational Study

Coutant

Nicolino²,

Cammas

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

ObjectiveTo study the impact of the true mean daily dose and the true mean number of injections per week on the yearly height gain in short children treated with recombinant human growth hormone (rhGH).Design and Methods220 children from the French Easypod™ Connect Observational Study (ECOS) used the Easypod™ electronic device to record rhGH injections. The mean daily rhGH dose (the sum of the doses truly received divided by the number of days) and mean number of injections per week (the number of injections truly performed divided by the number of weeks) were calculated. Linear mixed models were used to study the impact of short (3-month) and long (1-year) variations in rhGH administration on the yearly height change [as a standard deviation score (SDS)], with time on treatment as a covariate. For each patient, several periods of 3 or 12 months were considered and designated as poorly adherence or fully adherence. We studied the impact of each of period on the height change.ResultsAt treatment initiation, the mean ± SD age was 9.8 ± 3.7 years (females: 47%, prepubertal: 86%) and the mean height was -2.28 ± 0.92 SDS. The mean treatment duration was 3.2 ± 1.1 years (685.2 patient years). 122 patients were GH-deficient, 79 were small for gestational age, and 19 had Turner syndrome. When treatment was computed over 12-month periods, receiving a mean daily dose <0.03 mg/kg.d was associated with a 20% lower mean yearly height gain SDS when<3 injections/week were received (vs.>5 injections/week), whereas maintaining a mean daily dose >0.03 mg/kg.d with<3 injections/week was not associated with a lower yearly height gain SDS (vs.>5 injections/week). For 3-month periods, changes in the daily rhGH dose or the number of injections per week over such short period did not influence the yearly height gain SDS.ConclusionThe 12-month treatment model showed that when poor adherence leads to a low true daily GH dose, the yearly height gain is low. The 3-month treatment model showed that poor adherence for short periods (<3 months) had no impact on the height SDS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Yearly Height Gain Is Dependent on the Truly Received Dose of Growth Hormone and the Duration of Periods of Poor Adherence: Practical Lessons From the French Easypod™ Connect Multicenter Observational Study

Coutant

Nicolino²,

Cammas

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…A large number of clinical studies suggest that childhood and adolescent GH deficiency are associated with an increased risk of MAFLD ( 8 , 9 ). By definition, ISS is defined as short stature in childhood with no known aetiology, and although there is no clear cause, some researchers have attempted to explain the underlying mechanism of impaired linear growth in children with ISS ( 4 , 10 ). The GH/IGF-1 axis plays an important role during the critical period of childhood growth and development.…”

Section: Introductionmentioning

confidence: 99%

Association between the uric acid to high density lipoprotein cholesterol ratio and alanine transaminase in Chinese short stature children and adolescents: A cross-sectional study

Zhao

Zhang

et al. 2023

Front. Nutr.

View full text Add to dashboard Cite

ObjectiveUric acid to high-density lipoprotein cholesterol ratio (UHR), the ratio of uric acid to high-density lipoprotein cholesterol, is a newly proposed marker of metabolic abnormalities. There are few previous studies directly investigating the relationship between UHR and alanine aminotransferase (ALT), especially in short stature populations, however, short stature children and adolescents are more likely to have metabolic disorders. This research aimed to investigate the relationship between the UHR and ALT in children and adolescents with short stature.MethodsIn this cross-sectional analysis, the clinical data of 1,510 children with height below −2 SD who were evaluated at the Department of Endocrinology, Affiliated Hospital of Jining Medical University from 1 March 2013 to 31 December 2021, were selected. Anthropometric and biochemical indicators were measured. The relationship between UHR and ALT was analysed.ResultsThe univariate analysis results showed that UHR was positively associated with ALT (β = 0.43, P < 0.0001). Furthermore, after adjusting for possible confounding factors, a non-linear relationship was detected between UHR and ALT through smooth curve fitting, and the inflection point of UHR was 10.93% after multivariate piecewise linear regression analysis. ALT increased with UHR elevation when the UHR was greater than 10.93% (β = 0.69, 95% CI 0.39, 0.98; P < 0.0001). However, we did not observe a significant relationship when the UHR was less than 10.93% (P = 0.9229).ConclusionOur study demonstrated that in Chinese children and adolescents with short stature, UHR may be associated with the regulation of ALT levels, and this relationship merits further investigation.

show abstract

“…A large number of clinical studies suggest that childhood and adolescent GH de ciency are associated with an increased risk of MAFLD [8,9]. By de nition, ISS is de ned as short stature in childhood with no known aetiology, and although there is no clear cause, some researchers have attempted to explain the underlying mechanism of impaired linear growth in children with ISS [10,11]. The GH/IGF-1 axis plays an important role during the critical period of childhood growth and development.…”

Section: Introductionmentioning

confidence: 99%

Association between the uric acid to high density lipoprotein cholesterol ratio and alanine transaminase in Chinese short stature children and adolescents: a cross-sectional study

Zhao

Zhang

et al. 2022

Preprint

View full text Add to dashboard Cite

Objective This research aimed to investigate the relationship between the uric acid to high-density lipoprotein cholesterol ratio (UHR) and alanine aminotransferase (ALT) in children and adolescents with short stature. Methods In this cross-sectional analysis, the clinical data of 1510 children with height below − 2 SD who were evaluated at the Department of Endocrinology, Affiliated Hospital of Jining Medical University from March 1, 2013, to December 31, 2021, were selected. Anthropometric and biochemical indicators were measured.The relationship between UHR and ALT was analysed. Results The univariate analysis results showed that UHR was positively associated with ALT (β 0.43, P < 0.0001). Furthermore, after adjusting for possible confounding factors,a nonlinear relationship was detected between UHR and ALT through smooth curve fitting, and the inflection point of UHR was 10.93% after multivariate piecewise linear regression analysis. ALT increased with UHR elevation when the UHR was greater than 10.93% (β 0.69, 95% CI 0.39, 0.98; P < 0.0001). However, we did not observe a significant relationship when the UHR was less than 10.93% (P = 0.9229). Conclusion Our study demonstrated that in Chinese children and adolescents with short stature, UHR may be associated with the regulation of ALT levels, and this relationship merits further investigation.

show abstract

The continuum between GH deficiency and GH insensitivity in children

Cited by 4 publications

References 51 publications

Yearly Height Gain Is Dependent on the Truly Received Dose of Growth Hormone and the Duration of Periods of Poor Adherence: Practical Lessons From the French Easypod™ Connect Multicenter Observational Study

Yearly Height Gain Is Dependent on the Truly Received Dose of Growth Hormone and the Duration of Periods of Poor Adherence: Practical Lessons From the French Easypod™ Connect Multicenter Observational Study

Association between the uric acid to high density lipoprotein cholesterol ratio and alanine transaminase in Chinese short stature children and adolescents: A cross-sectional study

Association between the uric acid to high density lipoprotein cholesterol ratio and alanine transaminase in Chinese short stature children and adolescents: a cross-sectional study

Contact Info

Product

Resources

About